France challenges EU approval process for GMOs


Brussels/Paris – The French EU presidency is challenging the current EU process for market authorisation of genetically modified organisms (GMOs). At the beginning of the French term, environment minister Jean-Louis Borloo announced that a new ad-hoc committee will define additional criteria for the risk assessment procedure carried out by the European Food Safety Authority (EFSA).

In addition to the scientific evaluation of whether GMOs pose a potential danger to human health or the environment, France and other GMO-sceptic EU member states are seeking to implement an assessment of the socio-economic impact of GMO acreage, its usefulness, and an improved examination of its long-term effects on the environment. Borloo’s announcement was accompanied by demands from some EU member states to permit national market bans on GMO acreage. Experts expect another de facto-GMO moratorium if the new procedures are given the green light by the Commission. The Commission, however, which had already established an expert group to review its GMO policy, showed no interest in changing the current approval system. While France and GMO-sceptic governments have sought to weaken EFSA to gain more control over the assessment process that precedes GMO market approval, the Commission has strengthened EFSA’s position.

Commission stands behind EFSA

“France’s move is intended to nullify the meaningful separation of scientific and political decisionmaking on GMOs,” EU insiders told EuroBiotechNews. “Once the addition of political topics to the risk assessment prodedure leads to a situation where the EFSA appears to be undecided, GMO sceptics will say: ‘Look, there’s dissent over the safety of GMOs.” The battle that GMO-sceptic member states are waging against the current system of GMO approval and EFSA, which has yet to reject a market application on scientific grounds, will come to a head in December. One week before Christmas, EU environment
ministers will ask EU heads of state to change the criteria for GMO risk assessment. At the same time, EFSA is expected to publish a scientific opinion on the safety of npt2, an antibiotic marker used in BASF Plant Science’s GM potato Amflora (see p. 10). If positive, the scientific statement, which was requested by the Commission, will lead to the first approval for commercial acreage of a GM crop in Europe since 1998. EU insiders believe the Commission systematically prepared EFSA for the attack under the French presidency, and say the authority was told to update its guidelines
for GMO risk assessment before France took over. EFSA has also moved to address criticism about transparency; in June, the authority invited experts to lend their expertise to its decisions.



Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...



Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...



Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....



Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...



French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...



French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...



Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%


  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%


  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%


  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • WILEX (D)1.46 EUR-13.6%


  • NICOX (F)10.29 EUR430.4%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK81.6%


  • BB BIOTECH (D)44.30 EUR-82.9%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)92.00 GBP-73.1%

No liability assumed, Date: 30.08.2016


All Events